Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$2.49B |
| 2 |
NVIDIA
NVDA
|
+$2.19B |
| 3 |
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
|
+$1.94B |
| 4 |
TSMC
TSM
|
+$728M |
| 5 |
UnitedHealth
UNH
|
+$705M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$775M |
| 2 |
AbbVie
ABBV
|
+$540M |
| 3 |
Delta Air Lines
DAL
|
+$434M |
| 4 |
Eli Lilly
LLY
|
+$433M |
| 5 |
DexCom
DXCM
|
+$433M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 4.89% |
| 2 | Healthcare | 2.92% |
| 3 | Financials | 2.71% |
| 4 | Consumer Discretionary | 2.52% |
| 5 | Industrials | 2.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
12276
CALL
SkinHealth Systems
SKIN
$86.8M
| $21.8K | ﹤0.01% |
15,700
-16,200
| -51% | -$23.4K |
|
|
CRE
12277
Cre8 Enterprise Ltd
CRE
$5.42M
| $21.8K | ﹤0.01% |
+7,872
| New | +$44.3K |
|
|
PVL
12278
PUT
Permianville Royalty Trust
PVL
$58.1M
| $21.8K | ﹤0.01% |
+12,100
| New | +$21.8K |
|
12279
Torrid Holdings
CURV
$219M
| $21.7K | ﹤0.01% |
22,222
-852,386
| -97% | -$1.09M |
|
12280
CALL
Loop Industries
LOOP
$31.1M
| $21.7K | ﹤0.01% |
+21,700
| New | +$28.7K |
|
|
BBBY.WS
12281
Bed Bath & Beyond Warrants
BBBY.WS
| $21.7K | ﹤0.01% |
+32,875
| New | +$31.3K |
|
|
WORX
12282
DELISTED
SCWORX CORP NEW
WORX
| $21.7K | ﹤0.01% |
7,811
-308
| -4% | -$1.23K |
|
12283
PUT
Immunic
IMUX
$219M
| $21.6K | ﹤0.01% |
4,050
-740
| -15% | -$5.42K |
|
|
STAK
12284
STAK Inc
STAK
$33.8M
| $21.6K | ﹤0.01% |
54,125
+12,511
| +30% | +$7.49K |
|
12285
HCW Biologics
HCWB
$4.28M
| $21.5K | ﹤0.01% |
+3,693
| New | +$62.8K |
|
12286
PUT
Tenaya Therapeutics
TNYA
$163M
| $21.4K | ﹤0.01% |
30,100
+18,100
| +151% | +$24.6K |
|
|
PN
12287
PN Smart Energy Ltd
PN
$40.4M
| $21.3K | ﹤0.01% |
+1,477
| New | +$21.7K |
|
12288
Expion360
XPON
$3.47M
| $21.3K | ﹤0.01% |
+2,619
| New | +$38.3K |
|
12289
Seer Inc
SEER
$115M
| $21.3K | ﹤0.01% |
11,625
-4,799
| -29% | -$9.79K |
|
12290
Tenon Medical
TNON
$2.56M
| $21.2K | ﹤0.01% |
636
+94
| +17% | +$3.78K |
|
12291
BioVie
BIVI
$10.6M
| $21.1K | ﹤0.01% |
18,150
-86,381
| -83% | -$139K |
|
|
SVC
12292
CALL
Service Properties Trust
SVC
$1.05B
| $21K | ﹤0.01% |
2,280
-1,580
| -41% | -$15.9K |
|
12293
CALL
Lineage Cell Therapeutics
LCTX
$271M
| $20.9K | ﹤0.01% |
12,500
-105,500
| -89% | -$183K |
|
|
TRIB
12294
CALL
Trinity Biotech
TRIB
$7.88M
| $20.8K | ﹤0.01% |
+877
| New | +$25.9K |
|
12295
CALL
Urban One Class D
UONEK
$23.4M
| $20.8K | ﹤0.01% |
+2,420
| New | +$17.7K |
|
|
ALPS
12296
ALPS Group Inc
ALPS
$53.2M
| $20.7K | ﹤0.01% |
+23,837
| New | +$24.8K |
|
12297
Maison Solutions
MSS
$1.25M
| $20.4K | ﹤0.01% |
+1,287
| New | +$38K |
|
|
QNME
12298
Quanome Technologies
QNME
$15.9M
| $20.3K | ﹤0.01% |
22,788
-10,758
| -32% | -$11.3K |
|
|
TEAD
12299
CALL
Teads Holding Co
TEAD
$66.8M
| $20.2K | ﹤0.01% |
+28,700
| New | +$30.4K |
|
12300
CALL
Research Frontiers
REFR
$15.3M
| $20.2K | ﹤0.01% |
15,400
-135,900
| -90% | -$229K |
|
Similar funds
Ken Griffin's Q4 2025 Portfolio in Review
As of Q4 2025, Ken Griffin held 14,701 positions worth $666B, up 1.3% from $657B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Ken Griffin's Q4 2025 filing shows 2,078 new, 5,000 increased, 5,362 reduced and 2,191 closed positions. Its largest new stake was Medline Inc: 6,006,339 shares worth $252M. The largest sale was Meta Platforms (Facebook), an estimated $775M.
By sector, the portfolio is most concentrated in Technology at 4.9% of assets, up from 3.8% a quarter earlier, followed by Healthcare and Financials.
- Ken Griffin's largest Q4 2025 buy was Medline Inc: 6,006,339 shares worth $252M.
- Ken Griffin added most to Amazon in Q4 2025, an estimated $2.49B increase.
- Ken Griffin's biggest Q4 2025 reduction was Meta Platforms (Facebook), cutting an estimated $775M.
- Ken Griffin fully exited WEX in Q4 2025, selling an estimated $131M.
- Ken Griffin's ten largest holdings make up 23% of its $666B portfolio in Q4 2025.
- Ken Griffin opened 2,078 new positions and closed 2,191 in Q4 2025.
- Ken Griffin's portfolio value rose 1.3% quarter-over-quarter to $666B.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.